Table 3.
Cox regression analysis of variables impacting NSCLC patients treated with ICIs in relation to PFS.
| Variable | One-way analysis of variance | Multifactorial analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Age>60 | 1.258 (1.116-1.325) | 0.356 | – | – |
| Male | 1.410 (1.332-1.518) | <0.001 | – | – |
| Smoking | 1.625 (1.482-1.709) | <0.001 | – | – |
| Combined BLI | 0.338 (0.213-0.461) | <0.001 | 0.619 (0.524-0.791) | <0.001 |
| PS Rating | ||||
| 0~1 | 1 | – | – | – |
| 2~3 | 1.604 (1.472-1.739) | 0.882 | – | – |
| Squamous cancer | 0.632 (0.403-0.728) | <0.001 | – | – |
| PD-L1 expression | ||||
| Negatives | 1 | – | – | – |
| 1%~49% | 1.299 (1.142-1.390) | 0.583 | – | – |
| ≥50% | 1.258 (1.132-1.347) | 0.277 | – | – |
| Treatment programme | ||||
| Immunological monotherapy | 1 | – | – | – |
| Combination chemotherapy | 0.751 (0.669-0.802) | 0.611 | – | – |
| Combination radiotherapy | 1.206 (1.114-1.257) | 0.352 | – | – |
| Combined anti-angiogenic therapy | 1.547 (1.429-1.616) | 0.329 | – | – |
| Number of immunotherapy lines | ||||
| ≥2 | 1 | – | 1 | – |
| 1 | 0.320 (0.274-0.458) | <0.001 | 0.392 (0.288-0.463) | <0.001 |